IGF-1 replacement

Mecasermin

Prepared by the ezGLP team. Sources last checked September 5, 2026.

Also known as Recombinant human IGF-1, rhIGF-1

Routes represented in the knowledgebase: Subcutaneous (SubQ).

Educational overview

FDA-approved for severe primary IGF-1 deficiency in children, not for bodybuilding or general anti-aging use; can cause severe hypoglycemia.

Category: IGF-1 replacement
Routes represented: Subcutaneous (SubQ)
Storage context: Follow the dispensed product or pharmacy label; storage and beyond-use time vary by formulation.

Authoritative overview

Published literature

No validated PubMed or DOI link is currently curated for this entry.

Safety evidence

Common or reported: hypoglycemia, injection-site reactions, tonsillar enlargement, snoring, headache.

Serious or important: hypoglycemic seizure, intracranial hypertension, anaphylaxis, malignant-neoplasia warning.

Safety evidence source

Interaction evidence

These are general, pairwise evidence notes. Green identifies the potential-synergy category, while Lv3/Lv2/Lv1 communicates evidence strength; it does not guarantee benefit or cancel a safety warning.

With insulin or other glucose-lowering medicines

Safety flag

Mecasermin has insulin-like effects and can add to medication-related hypoglycemia.

Interaction evidence source

With Ipamorelin

Safety flag

Duplicate GH/IGF-axis stimulation may amplify IGF-1 elevation, edema, joint symptoms, and glucose intolerance.

Interaction evidence source

Summarised from published literature for reference only, with citations to the source. Evidence is graded as reported and is not a recommendation to combine, dose, or use any compound.

For personal tracking and education only. Not medical advice, diagnosis, or treatment, and not a medical device. Peptides may be prescription-only or unapproved where you live — consult a licensed healthcare professional.